Showing 1491-1500 of 1635 results for "".
- Kala Pharmaceuticals Announces Statistically Significant Results in STRIDE 3 Trial of Dry Eye Disease Drug Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-statistically-significant-results-in-stride-3-trial-of-dry-eye-disease-drug-eysuvis/2477360/Kala Pharmaceuticals announced positive topline results from STRIDE 3, a phase 3 clinical trial evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. STRIDE 3 met b
- Alcon Launches Systane MyEyes to Increase Continuity of Care and Patient Retention Following iLUX MGD Treatmenthttps://modernod.com/news/alcon-launches-systane-myeyes-to-increase-continuity-of-care-and-patient-retention-following-ilux-mgd-treatment/2477353/Alcon has introduced Systane MyEyes, a new patient support program focused on increasing continuity of care and retention. It is the first-and-only comprehensive program focused on supporting and educating patients about the chronic and progressive nature of meibomian gland dysfunction (MGD) and
- CooperVision Announces Availability of Biofinity Toric Multifocal Contact Lenseshttps://modernod.com/news/coopervision-announces-availability-of-biofinity-toric-multifocal-contact-lenses/2477352/To enable eye care professionals to address their astigmatic patients’ evolving presbyopic needs, CooperVision has announced the availability of its new Biofinity toric multifocal contact lenses. The company has begun initial shipments of the lenses, with nationwide availability expected in May.<
- AAO Alert: Coronavirus Update for Ophthalmologistshttps://modernod.com/news/aao-alert-coronavirus-updates-for-ophthalmologists/2477347/The Academy is sharing important ophthalmology-specific information related to the novel coronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was previously known by the provisional name 2019-nCoV. The highly contagious virus can cause a severe respirato
- The American Optometric Association (AOA) Partners With Lyft To Offer Free Rides To Get A Comprehensive Eye Examhttps://modernod.com/news/the-american-optometric-association-aoa-partners-with-lyft-to-offer-free-rides-to-get-a-comprehensive-eye-exam/2477334/The American Optometric Association (AOA), the leading authority on quality care and an advocate for our nation’s health, representing more than 30,000 doctors of optometry, announced that it is working with Lyft, the transportation network, to offer free rides to people in select cities in
- Gyroscope Therapeutics Strengthens Senior Leadership Ahead of Next Stage of Company Growthhttps://modernod.com/news/gyroscope-therapeutics-strengthens-senior-leadership-ahead-of-next-stage-of-company-growth/2477297/Gyroscope Therapeutics announced the strengthening of its leadership team with the hiring of Nadia Waheed, MD, MPH, from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO), and the promotion of Jane Hughes, PhD, formerly VP Translational Research, to Chief Scientific Off
- Market Scope: Miami, Philadelphia, and Virginia Beach in Top 10 Markets of Glaucoma Treatment Opportunityhttps://modernod.com/news/market-scope-miami-philadelphia-and-virginia-beach-in-top-10-markets-of-glaucoma-treatment-opportunity/2477291/The metro areas of New York, Los Angeles, Dallas, and Chicago account for 13 percent of the US glaucoma and ocular hypertension population. However, on a per capita share basis, most of the metro areas in Florida stand out for glaucoma disease, driven largely by the state’s high median age. Naple
- Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)https://modernod.com/news/oculis-announces-positive-ocs-01-phase-2-data-in-patients-with-diabetic-macular-edema-dme/2477287/Oculis reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment of diabetic macular edema (DME), according to a company news release. OCS-01 was developed using Oculis’ proprietary Soluble NanoParticle technolog
- Kodiak Sciences Announces Additional Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-additional-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-diseases/2477282/Kodiak Sciences announced promising safety, efficacy, and durability data from the ongoing phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degener
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N